Condition (MeSH)
Erythema Multiforme
ClinicalTrials.gov lists 53 trials for Erythema Multiforme or a narrower condition beneath it. Austrian Breast & Colorectal Cancer Study Group has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
14 of the 53 trials are tagged with Erythema Multiforme itself; the rest are tagged with a narrower condition beneath it.
When did Erythema Multiforme trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 2 |
| 2020 | 4 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 5 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Erythema Multiforme trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 8 |
| Phase 2 | 4 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |
| Phase 4 | 4 |
| Not applicable | 14 |
| Observational | 14 |
| Expanded access | 1 |
How many Erythema Multiforme trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 3 |
| Available | 1 |
| Completed | 23 |
| Terminated | 4 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Erythema Multiforme trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Austrian Breast & Colorectal Cancer Study Group | 1 |
Which drugs are being tested for Erythema Multiforme? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (CP-6890,550) Tofacitinib | 2 |
| INFLIXIMAB | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Site specific standard of care comparison | 1 |
| cultivated oral mucosal epithelial sheet transplantation | 1 |
| Adipose derived stromal cells intravenously injected | 1 |
| NaCl 0.9% NS | 1 |
| Harmonized supportive care | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Erythema Multiforme trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Corneal transplant | 2 | 1 |
| Cystoid macular oedema | 2 | 1 |
| Intraocular pressure increased | 2 | 1 |
| Retinal detachment | 2 | 1 |
| Retinopathy proliferative | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Erythema Multiforme? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. | Lancet (London, England) | 2024 | Yes |
| Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. | The Journal of investigative dermatology | 2022 | Yes |
| Drug-mediated rash: erythema multiforme versus Stevens-Johnson syndrome. | BMJ case reports | 2014 | Yes |
| Radiodermatitis: A Review of Our Current Understanding. | American journal of clinical dermatology | 2016 | No |
| Diagnostic pathways and clinical significance of desquamative gingivitis. | Journal of periodontology | 2008 | No |
Showing 5 of 7 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.